| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/27/2006 | WO2006077853A1 Therapeutic agent for sensory abnormality |
| 07/27/2006 | WO2006077851A1 Quinolone derivative and salt thereof |
| 07/27/2006 | WO2006077846A1 Therapeutic agent for attention-deficit hyperactivity disorder |
| 07/27/2006 | WO2006077821A1 Aromatic sulfone compound as aldosterone receptor modulator |
| 07/27/2006 | WO2006077816A1 Imidazopyridine derivative |
| 07/27/2006 | WO2006077793A1 Antitumor agent |
| 07/27/2006 | WO2006077724A1 Cancer vaccine preparation |
| 07/27/2006 | WO2006077499A1 Chemical compounds |
| 07/27/2006 | WO2006077497A1 Crystalline forms cis-5-fluoro-n-[4-(2-hydroxy-4-methylbenzamido) cyclohexyl]-2-(tetrahydrothiopyran-a-yloxy) nicotinamide |
| 07/27/2006 | WO2006077496A1 Substituted triazole derivatives as oxytocin antagonists |
| 07/27/2006 | WO2006077495A1 Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases |
| 07/27/2006 | WO2006077494A2 A process for preparing solid dosage forms for extended-release of biguanide and sulfonylurea |
| 07/27/2006 | WO2006077492A1 Sustained release oral dosage forms of gabapentin |
| 07/27/2006 | WO2006077487A1 3,4-dihydro-2-naphthamide derivatives and their therapeutic applications |
| 07/27/2006 | WO2006077429A1 Anthelmintic composition |
| 07/27/2006 | WO2006077428A1 Pharmaceutical compounds |
| 07/27/2006 | WO2006077427A2 Antiviral drug combinations |
| 07/27/2006 | WO2006077426A2 4- (2, 6-DICHLOROBENZOYLAMINO) -lH-PYRAZOLE-3 -CARBOXYLIC ACID PIPERIDIN- 4 -YLAMID ACID ADDITION SALTS AS KINASE INHIBITORS |
| 07/27/2006 | WO2006077425A1 Combinations of pyrazole kinase inhibitors and further antitumor agents |
| 07/27/2006 | WO2006077424A1 Pharmaceutical compounds |
| 07/27/2006 | WO2006077419A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | WO2006077416A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | WO2006077414A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | WO2006077412A1 Thienopyrroles useful in the treatment of inflammation |
| 07/27/2006 | WO2006077410A1 Method of treatment by administration of rna |
| 07/27/2006 | WO2006077409A1 Method of genotypically modifying cells by administration of rna |
| 07/27/2006 | WO2006077401A1 Pyrrolopyridines useful in the treatment of inflammation |
| 07/27/2006 | WO2006077367A1 Indoles useful in the treatment of inflamation |
| 07/27/2006 | WO2006077366A1 Indoles useful in the treatment of inflammation |
| 07/27/2006 | WO2006077365A1 Indoles useful in the treatment of inflammation |
| 07/27/2006 | WO2006077364A1 Indoles useful in the treatment of inflammation |
| 07/27/2006 | WO2006077320A1 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application |
| 07/27/2006 | WO2006077319A1 Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use |
| 07/27/2006 | WO2006077309A1 Injectable pharmaceutical composition containing a catecholamine and a peptidic hormone |
| 07/27/2006 | WO2006077217A1 New 3-phenylpropionic acid derivatives |
| 07/27/2006 | WO2006077212A1 Use of oxycodone for treating visceral pain |
| 07/27/2006 | WO2006077206A1 New 3-phenylpropionic acid derivatives and their use as ppar- gamma rezeptor liganden |
| 07/27/2006 | WO2006077202A1 Novel nutraceutical compositions |
| 07/27/2006 | WO2006077168A1 Pyrazolopyridines, their preparation and their medical use |
| 07/27/2006 | WO2006077166A1 Use of gallium (iii) complexes for treating tumours of the urothelial tract |
| 07/27/2006 | WO2006077139A2 Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same |
| 07/27/2006 | WO2006077026A1 2, 5-disubstituted phenyl methanone derivatives as glycine transporter 1 (glyt-i) inhibitors for the treatment of neurological and neuropsychiatry disorders |
| 07/27/2006 | WO2006077025A2 Morpholines as 5ht2c agonists |
| 07/27/2006 | WO2006077024A2 5-aminoindole derivatives |
| 07/27/2006 | WO2006077013A1 Tetrahydrofurane derivatives for use as inhibitors of matrix metalloproteinases |
| 07/27/2006 | WO2006077012A2 USE OF LXR LIGANDS FOR THE MODULATION OF DENDRITIC CELLS (DCs) |
| 07/27/2006 | WO2006076951A1 Pharmaceutical polymer composition for oral controlled-release delivery of terbutaline sulfate |
| 07/27/2006 | WO2006076863A1 The synergistically pharmaceutical composition for inhibiting tumor |
| 07/27/2006 | WO2006076854A1 Combination medication for malignant tumors and application |
| 07/27/2006 | WO2006076844A1 Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof |
| 07/27/2006 | WO2006076797A1 Cathepsin k inhibitors and atherosclerosis |
| 07/27/2006 | WO2006076796A1 Cathepsin k inhibitors and obesity |
| 07/27/2006 | WO2006076767A1 A method of treating cellular damage |
| 07/27/2006 | WO2006066173A3 Novel mch receptor antagonists |
| 07/27/2006 | WO2006065881A3 Use of ribose to alleviate rhabdomyolysis and the side effects of statin drugs |
| 07/27/2006 | WO2006062581A3 Delivery of therapeutic rnai agents for treating restenosis |
| 07/27/2006 | WO2006061712A3 Use of mek inhibitors in treating abnormal cell growth |
| 07/27/2006 | WO2006060712A9 Potassium salt of an hiv integrase inhibitor |
| 07/27/2006 | WO2006058720A3 Novel compounds for the treatment of neurological disorders |
| 07/27/2006 | WO2006054143A8 Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine |
| 07/27/2006 | WO2006053555A3 Pyrazol-3-one and/or pyridazin-3-one derivatives used as inhibitors of lysyl oxidase |
| 07/27/2006 | WO2006053252A3 Methods of treating hematological malignancies with nucleoside analog drugs |
| 07/27/2006 | WO2006052626A3 Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders |
| 07/27/2006 | WO2006050826A3 Treatment of mastitis with enrofloxacin |
| 07/27/2006 | WO2006050480A3 Substituted pyridines with activity on syk kinase |
| 07/27/2006 | WO2006050373A3 Methods and compositions for modulating apoptosis |
| 07/27/2006 | WO2006050250A3 Dose forms comprising vx-950 and their dosage regimen |
| 07/27/2006 | WO2006050246A3 Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles, their manufacturing and their use for diagnostics and therapy |
| 07/27/2006 | WO2006045799A3 Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions |
| 07/27/2006 | WO2006042857A3 Complex containing mequitazine, a cyclodextrin and an interaction agent |
| 07/27/2006 | WO2006041922A3 Agents and methods for administration to the central nervous system |
| 07/27/2006 | WO2006037958A3 Treatment of helminth infection by inhibition of tyrosinase |
| 07/27/2006 | WO2006037029A3 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 07/27/2006 | WO2006036981A3 Small molecule modulators of cytokine activity |
| 07/27/2006 | WO2006036916A3 Rnai modulation of apob and uses thereof |
| 07/27/2006 | WO2006035433A3 Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride |
| 07/27/2006 | WO2006034468A9 Methods and compositions for treating hyperglycemic, hyperlipidemic, or hyperinsulinemic disorders |
| 07/27/2006 | WO2006034333A3 Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives |
| 07/27/2006 | WO2006034315A3 Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| 07/27/2006 | WO2006034154A3 Salts of 5-azacytidine |
| 07/27/2006 | WO2006027344A3 3-oxa-10-aza-phenanthrenes as pde4 or pde3/4 inhibitors |
| 07/27/2006 | WO2006026204A3 Novel gamma-lactams as beta-secretase inhibitors |
| 07/27/2006 | WO2006023750A3 Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 07/27/2006 | WO2006020017A3 Dipeptidyl peptidase inhibitors |
| 07/27/2006 | WO2006020004A3 Histone deacetylase inhibitors |
| 07/27/2006 | WO2006019978A9 Compositions and methods for diagnosis and treatment of epilepsy |
| 07/27/2006 | WO2006018735A8 Triazolopyridine compounds |
| 07/27/2006 | WO2006015970A3 Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| 07/27/2006 | WO2006015263A3 Lonidamine analogs |
| 07/27/2006 | WO2006014647A3 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof |
| 07/27/2006 | WO2006013203A3 Prodrugs activated by rna-dependent dna-polymerases |
| 07/27/2006 | WO2006012642A3 Pyrrole derivatives as pharmaceutical agents |
| 07/27/2006 | WO2006012226A3 N-substituted piperidines and their use as pharmaceuticals |
| 07/27/2006 | WO2006008316A3 Selective inhibitors of human corticosteroid syntheses |
| 07/27/2006 | WO2006007501A3 Mitotic kinesin inhibitors |
| 07/27/2006 | WO2006001967A3 Migrastatin analogs in the treatment of cancer |
| 07/27/2006 | WO2005124343A3 Methods for modulating bone tissue formation, orthogenic agents and pharmaceutical compositions |
| 07/27/2006 | WO2005120498A3 Method for synthesis of lonidamine and related indazole derivatives |
| 07/27/2006 | WO2005118166A3 Pharmaceutical composition containing irbesartan |
| 07/27/2006 | WO2005117904A3 Phosphonate analogs of hiv integrase inhibitor compounds |